Clinical Studies: 2010 Start Date

Psoriasis
Sponsor: Wyeth
A Single Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of ILV-095 Administered Subcutaneously to Subjects With Psoriasis
April 2010 to Present

Healthy Volunteer Program
Sponsor: Eli Lilly & Co.
Biomarker Study of the Smoothened Pathway in Healthy Volunteers
April 2010 to May 2010

Atopic Dermatitis
Sponsor: Novartis
A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Pimecrolimus 1% Cream (PEER Registry)
March 2010 to Present

Asthma
Sponsor: GlaxoSmithKline
A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma
March 2010 to Present

COPD
Sponsor: Forest Laboratories
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the 2 Aclidinium Bromide Dose
March 2010 to Present

Psoriasis
Sponsor: Amgen, Inc.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
February 2010 to Present

Psoriatic Arthritis
Sponsor: Centocor, Inc
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
February 2010 to Present

Clinical Studies